- Report
- July 2024
- 190 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- July 2024
- 181 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- July 2024
- 189 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- July 2024
- 182 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- June 2024
- 180 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- May 2024
- 182 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- May 2024
- 182 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- May 2024
- 185 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- June 2024
- 200 Pages
Global
From €7226EUR$7,950USD£6,136GBP
- Drug Pipelines
- April 2025
- 450 Pages
Global
From €4545EUR$5,000USD£3,859GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Report
- August 2024
- 116 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- June 2024
- 182 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- July 2024
- 120 Pages
Global
From €4317EUR$4,750USD£3,666GBP
- Report
- April 2025
- 150 Pages
Global
From €4408EUR$4,850USD£3,743GBP
- Report
- March 2025
- 150 Pages
Global
From €4408EUR$4,850USD£3,743GBP
- Report
- March 2025
- 150 Pages
Global
From €4408EUR$4,850USD£3,743GBP
- Report
- September 2024
- 150 Pages
Global
From €4408EUR$4,850USD£3,743GBP
- Report
- December 2024
- 200 Pages
Global
From €3409EUR$3,750USD£2,894GBP
- Report
- December 2024
- 200 Pages
Global
From €3409EUR$3,750USD£2,894GBP

The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more